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http://dx.doi.org/10.1016/j.pedneo.2
1875-9572/Copyright ª 2015, TaiwanBackground: Neonatal sepsis is an important cause of neonatal morbidity and mortality in the
neonatal intensive care unit. Soluble triggering receptor expressed on myeloid cells-1 (sTREM-
1) has been evaluated in sepsis and septic shock, and it was found to be valuable in distinguish-
ing septic cases from nonseptic cases. Endocan is constitutively expressed by endothelial cells,
and high levels of endocan may be of relevance for the promotion of systemic inflammation.
The aim of this study was to investigate whether the levels of sTREM-1 and endocan were
increased in late-onset neonatal sepsis.
Methods: Patients were classified into septic and nonseptic groups. Blood was collected from a
peripheral vein of all septic newborns and healthy newborns at the time of initial laboratory
evaluation before any treatment, and within 48e72 hours after initiation of treatment. Serum
sTREM-1 and endocan measurements were performed when the study was finished.
Results: The study population comprised of 50 neonates: 20 nonseptic neonates and 30 septic
neonates. The groups were similar with regards to baseline characteristics. The initial mea-
surements of interleukin-6 (IL-6), sTREM-1, endocan, and immature/total neutrophil ratio (I/
T ratio) were significantly higher in septic neonates in comparison with nonseptic neonates.itary School of Medicine, Department of Pediatrics, Division of Neonatology, 06018 Ankara, Turkey.
(T. Tunc).
015.03.006
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416 M. Saldir et alReceiver operating characteristic (ROC) curve analyses revealed that IL-6, sTREM-1, endocan,
and I/T ratio resulted in significant areas under the curve (AUC) with respect to early identi-
fication of septic neonates. Soluble TREM-1 and IL-6 performed best to distinguish septic neo-
nates from nonseptic neonates. Univariate logistic regression analysis showed that increased
IL-6 and sTREM-1 were strong predictors of neonatal late-onset sepsis.
Conclusion: Serum sTREM-1, IL-6, endocan levels, and I/T ratio increased in septic neonates.
However, the diagnostic accuracy of circulating sTREM-1 seemed to be better than endocan
and I/T ratio, but lower than IL-6.
Copyright ª 2015, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
In spite of advances in neonatal care, neonatal sepsis rep-
resents a serious problem in newborns. Late-onset sepsis
(LOS) in neonates is defined as infection becoming clinically
evident > 72 hours after birth, and it usually appears due to
nosocomially acquired organisms.1 One study revealed an
incidence of 0.44% for LOS with a mortality rate of 9%.2 Of
the neonates evaluated for neonatal sepsis, only 3e8% had
culture-proven sepsis. This disparity arose from the
cautious approach to the management of neonatal sepsis.3
Because early signs of sepsis in newborns are nonspecific,
diagnostic studies are often ordered and treatment initi-
ated in neonates before the presence of sepsis has been
proven.4 Since mortality from untreated sepsis could be as
high as 50%, most clinicians believed that the hazard of
untreated sepsis did not allow them to wait for confirma-
tion with positive culture results. Therefore, most clini-
cians initiate treatment in advance.5
Inflammation and endothelial activation are critical de-
terminants of the host response and represent an expla-
nation for the complex pathophysiology in sepsis.
Accordingly, biomarkers pertaining to inflammation and
endothelial activation might be useful in the diagnosis and
follow-up of sepsis. Human triggering receptor expressed
on myeloid cells-1 (TREM-1) is a 30-kDa glycoprotein
belonging to the immunoglobulin superfamily. It plays a
considerable role in the innate immune response against
invading microorganisms and is selectively expressed in
neutrophils and monocytes/macrophages.6 Expression of
TREM-1 is highly upregulated in septic states. Increased
levels of TREM trigger the release of proinflammatory cy-
tokines, increase surface expression of cell receptors, and
activate neutrophil degranulation. Additionally, expression
of TREM-1 is extremely upregulated in septic states and
thus is significantly increased in human blood (also known
as soluble form sTREM-1).7 In this context, sTREM-1 has
been evaluated in the blood of adults with sepsis, septic
shock, and community-acquired pneumonia and it was
found to be valuable in distinguishing infected from
noninfected patients.8,9
Endocan, initially known as endothelial cell-specific
molecule-1, is a soluble 50-kDa dermatan sulfate proteo-
glycan that is constitutively expressed by endothelial cells
in lungs and kidneys and can be detected in human blood.10Inflammatory cytokines, such as interleukin (IL)-1b and
tumor necrosis factor (TNF)-a, stimulate the upregulation
of endocan mRNA and the secretion of endocan from
endothelial cells.11 The secreted form circulates in the
human bloodstream and can be detected easily. It is sug-
gested that serum endocan levels were four-fold higher in
sepsis patients at intensive care unit admission compared
with healthy adult individuals. In the same study serum
endocan levels were found to be higher in patients with
septic shock than in patients with severe sepsis or sepsis,
representing endothelial damage and correlating with the
severity of disease and outcome. High levels of endocan
have also been detected in patients with cancer.12 Other
studies have described that endocan is not specific for
systemic inflammatory diseases. However, high levels of
endocan may be of relevance for the promotion of systemic
inflammation.13
The aim of this study was to investigate whether levels
of sTREM-1 and endocan were increased in infected neo-
nates at the first neonatal intensive-care unit (NICU)
admission, and to assess their possible value in early diag-
nosis and follow-up of LOS. We analyzed traditional bio-
markers, interleukin-6 (IL-6) and immature/total
neutrophil ratio (I/T ratio), as well as sTREM-1 and endocan
levels to evaluate septic neonates in NICUs.2. Methods2.1. Study design
This prospective study was conducted in two different level
III NICUs (Kanuni Sultan Su¨leyman Teaching and Research
Hospital, Ankara, Turkey and Gu¨lhane Military School of
Medicine, Istanbul, Turkey). The study protocol was
approved by the local Ethical Committee of Gulhane Mili-
tary School of Medicine and Teaching Hospital and written
informed consent was obtained from the first-degree rela-
tives before admission to the study. The study population
included late preterm (gestational age of > 34 weeks) and
term neonates who were evaluated for LOS during the
period of January 2012 to December 2012. Inclusion criteria
were postnatal age  72 hours, the presence of nonspecific
signs of sepsis (temperature instability, apneic spells, need
for supplemented oxygen, need for ventilation,
Table 1 Patient demographics.
Nonseptic
group (N Z 20)
Septic group
(N Z 30)
p
Gestational age (wk) 38.3  1.6 37.9  1.7 0.44
Birth weight (g) 3328  383 3201  313 0.20
Male sex 11 (55) 12 (40) 0.30
Maternal fever 5 (25) 8 (27) 0.27
Premature rupture
of membranes
4 (20) 5 (17) 1.00
Intrapartum
antibiotics
5 (25) 10 (33) 0.53
Cesarean section 6 (30) 12 (40) 0.47
Apgar at 1 min 8.3  0.7 8  0.9 0.22
Apgar at 5 min 9.6  0.5 9.3  0.6 0.16
Umbilical artery pH 7.21  0.08 7.19  0.07 0.38
Age at study entry (h) 93  16 99  24 0.34
Data are presented as n (%) or mean  SD.
Novel Markers for Neonatal Sepsis 417tachycardia/bradycardia, hypotension, feeding intoler-
ance, abdominal distension, and necrotizing enterocolitis),
and clinical deterioration considered to be due to sepsis.
Patients who were referred to our center or outpatients
with suspected sepsis during the study period were
included in the study. Babies born to mothers with clinical
chorioamnionitis, babies who were diagnosed with sepsis in
the first 72 hours of life, those who used antibiotic treat-
ment for early-onset sepsis, and those who had congenital
infections and anomalies were excluded. During the study
period a total of 53 patients were evaluated with suspected
sepsis. Of these, 23 were excluded from the study because
of the criteria mentioned above.
2.2. Diagnosis of infection
Patients were classified according to the criteria reported
by Gitto et al14 They were classified into two groups: septic
and nonseptic. The septic group included neonates with
proven infection [positive blood or cerebrospinal fluid (CSF)
cultures for microorganisms] and probable infection
(negative cultures but clinical and laboratory evidence of
sepsis: C-reactive protein (CRP) > 5 mg/dL,  3 sepsis-
related clinical signs). Patients who were initially hospi-
talized with suspected sepsis but in whom the diagnosis of
sepsis was not supported by clinical or laboratory findings
were included as the nonseptic group. All patients in both
groups were administered antibiotics initially according to
standard protocols. Antibiotic treatments were dis-
continued in patients without sepsis, according to clinical
and laboratory findings, after 48 hours. However, in pa-
tients with microbiologically diagnosed or clinically diag-
nosed sepsis, antibiotic therapies were given for at least 7
days. Patients with negative cultures and those with no
clinical/laboratory evidence of infection were classified as
the nonseptic group. The likelihood of infection was
assessed on admission and laboratory investigations
included complete blood count and differential, white
blood cell (WBC) and platelet counts, absolute neutrophil
count (ANC), I/T ratio, CRP, arterial blood gases, blood,
urine, and cerebrospinal fluid (CSF) cultures. Laboratory
evidence of infection was positive blood or CSF cultures,
metabolic acidosis, leukopenia/leukocytosis, thrombocy-
topenia, I/T neutrophil ratio  0.2, and CRP > 5 mg/dL.
Gestational age, birth weight, gender, survival, microor-
ganisms isolated from blood, CSF cultures, and Apgar score
at 1 minute and 5 minutes for all newborns were included in
the two groups (septic and nonseptic newborns).
2.3. Blood sampling
Blood was collected from a peripheral vein of all septic
newborns and nonseptic newborns at the time of initial
laboratory evaluation before any treatment and within
48e72 hours after initiation of treatment. Samples were
collected sterile tubes. After centrifugation, serum was
kept at 70C until analysis. Serum sTREM-1 (Human TREM-
1 Quantikine ELISA Kit; R&D Systems, Minneapolis, MN, USA)
and endocan (a sandwich-type enzyme-linked immunosor-
bent assay and expressed in ng/mL) measurements were
performed when the study was finished.112.4. Statistical analysis
SPSS for Windows 15.0 (SPSS Inc., Chicago, IL, USA) was
used for statistical analysis. Descriptive statistics were
presented as mean, standard deviation, median [inter-
quartile range (IQR)], frequency, and percent. The distri-
bution characteristics of continuous variables were
evaluated with Kolmogorov Smirnov test. Student t test was
used as a parametric test and ManneWhitney U test was
used as a nonparametric test, where appropriate. Paired t
test or Wilcoxon signed ranks test were used to compare
first and second measures in the study group as appro-
priate. Pearson Chi-square test or Fisher’s exact test were
used to compare categorical variables as appropriate.
Spearman rho correlation test was used to determine the
linear association between variables. Receiver operating
characteristic (ROC) curve analysis was used to determine
the best cut-off points for IL-6, sTREM-1, endocan, and I/T
ratio. Then sensitivity, specificity, positive and negative
predictive values, and positive and negative likelihood ra-
tios were calculated with respect to determined cut-off
values. Univariate logistic regression analysis was used to
calculate odds ratio (OR) values. A p value < 0.05 was
accepted as statistically significant.3. Results
The study population comprised of 50 neonates: 20 non-
septic patients and 30 septic patients (6 with proven sepsis
and 24 with probable sepsis). Demographic characteristics
of the patients are shown in Table 1, and the groups were
similar with regards to baseline characteristics. Six patients
developed positive blood cultures: three of Gram-positive
and three of Gram-negative microorganisms. The patho-
gens of six participants with positive blood culture were as
follows: Staphylococcus aureus (1), coagulase-negative
staphylococcus (CoNS) (2), Klebsiella spp. (2), and Escher-
ichia coli (1). Urine and CSF cultures were negative in all
infants. No infant died in either group.
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were significantly higher at the time of sepsis diagnosis
(sepsis 1) in the septic group as compared with the non-
septic group. Further, there was a significant difference
between the septic and nonseptic groups with respect to
the levels of I/T ratio (Table 2). There was a statistically
significant difference between the first (sepsis 1) and the
second values (sepsis 2) of septic groups’ measurements of
IL-6 (median Z 19, IQR Z 11.832.5 ng/mL versus
median Z 5, IQR Z 2.06.5 ng/mL, p < 0.001), sTREM-1
(median Z 985, IQR Z 5761400 pg/mL versus
median Z 836.6, IQR Z 702.2944.8 pg/mL, p Z 0.028),
endocan (median Z 29, IQR Z 22.538.0 ng/mL versus
medianZ 19.7, IQRZ 17.221.1 ng/mL, p < 0.001), and I/
T ratio (median Z 0.27, IQR Z 0.190.36 versus
median Z 0.12, IQR Z 0.100.16, p < 0.001) (Figure 1).
ROC curve analyses revealed that IL-6, sTREM-1, endo-
can, and I/T ratio resulted in significant areas under the
curve (AUC) with respect to early identification of septic
neonates. Soluble TREM-1 and IL-6 performed best to
distinguish septic neonates from nonseptic neonates. The
AUC was 0.97 [95% confidence interval (CI)Z 0.9310.998,
p < 0.001] for sTREM-1 and 0.96 for IL-6 (95%
CIZ 0.9080.998, p < 0.001) whereas the AUC was 0.80 for
endocan (95% CIZ 0.674e0.923, p < 0.001) and 0.90 for I/T
ratio (95% CI Z 0.8260.987, p < 0.001). Table 3 summa-
rizes the optimal cut-off point, sensitivity, specificity,
positive and negative predictive value, and positive and
negative likelihood ratio for each biomarker, respectively.
In the next step, taking into account the cut-off values
for these four biomarkers, the relationship between bio-
markers and sepsis was examined using both univariate and
multivariate logistic regression analysis. Univariate logistic
regression analysis showed that all variables were associ-
ated with sepsis and the probability of sepsis also rose with
the increasing values of each biomarkers. According to
univariate logistic regression analysis, increased IL-6 and
sTREM-1 were strong predictors of neonatal LOS. IL-6
showed the strongest association with neonatal LOS
[OR Z 266 (95% CI Z 22.503145.19), p < 0.001] followed
by sTREM-1 [OR Z 126, 95% CI Z 16.26976.27),
p < 0.001]. ORs for endocan and I/T ratio were found as
OR Z 7.7, 95% CI Z 2.127.5, p Z 0.002; OR Z 20.0 (95%
CI Z 4.785.9, p < 0.001, respectively; Table 4). Multi-
variate logistic regression analysis was performed to
determine which of these four biomarkers were the inde-
pendent predictors of sepsis, and IL-6 was found to be the
only independent predictor [ORZ 157.4 (10.802293.54)].
The other three biomarkers were not found to be statisti-
cally significant independent predictors of sepsis (Table 4).Table 2 IL-6, sTREM-1, endocan levels, and I/T ratio of patient
Septic group
Median IQR
IL-6 (pg/mL) 19.0 11.832.5
sTREM-1(pg/mL) 985 5761400
Endocan (ng/mL) 29 22.538
I/T ratio 0.27 0.190.36
I/T ratio Z immature by total ratio; IL-6 Z interleukin 6; sTREM-1 Z4. Discussion
The present study aimed to determine the predictive values
and the kinetics of serum sTREM-1, endocan, and other
cytokine concentrations in late preterm neonates and term
neonates with LOS. Our results revealed that the levels of
sTREM-1, endocan, and IL-6 increased significantly in the
serum of neonates with LOS, suggesting that sTREM-1 and
endocan had a considerable diagnostic performance to di-
agnose LOS and to monitor the response to therapy there-
after. To the best of our knowledge, this is the first study
investigating these two markers simultaneously.
LOS is a relatively frequent event in newborns admitted
to NICUs, and it is associated with a high rate of morbidity
and mortality.15 When septic infection occurs, microor-
ganisms invade the blood stream and release various sub-
stances that in turn activate the endogenous mediators of
the host systemic response. Various molecules such as CRP,
procalcitonin, sICAM-1, IL-6, IL-8, TNF-a, mean platelet
volume, CD 64 index, soluble e-selectin, p-selectin, and
serum amyloid A were found to be higher in the blood of
patients with sepsis. Accordingly, they were proposed as
markers of sepsis severity, but none gained wide clinical
acceptance because they generally reflected a single bio-
logical aspect of sepsis, which is a complex and heteroge-
neous process.16e18 Recently, sTREM-1 was shown to help
identify patients with infection and perhaps also to help
predict patients’ outcome in many studies.19 Increased
serum sTREM-1 levels have also been found in patients with
infectious shock, being closely correlated with the severity
of infection.20
Many clinical studies conducted on infected newborns
revealed that sTREM-1 could be considered to be a valuable
biomarker for assessing neonatal infections. Sarafidis et al19
recently reported elevated sTREM-1 levels in newborns with
possible LOS and confirmed LOS. They suggested that
sTREM-1 may be used for assessing nosocomial infections in
neonates but it was not better than IL-6 in discriminating
septic neonates. In our study, increased sTREM-1 levels
were strongly associated with LOS as well as IL-6. In addi-
tion, studies on critically ill adult patients showed
increased plasma sTREM-1 levels in sepsis patients
compared with patients without sepsis.21 Furthermore, in
the latter study, sTREM-1 was reported to be better than
some commonly used diagnostic biomarkers such as pro-
calcitonin and CRP in detecting sepsis. Nonetheless, it was
shown that increased sTREM-1 levels were not specific for
infection and could also increase markedly in acute
inflammation without infection.s at the first admission.
Nonseptic group p
Median IQR
1.0 03.8 < 0.001
73 60124.5 < 0.001
19.8 15.924.5 < 0.001
0.12 0.100.16 < 0.001
soluble triggering receptor expressed on myeloid cells-1.
Figure 1 (A)Serum levels of IL-6; (B) sTREM-1; (C) Endocan; and (D) I/T ratio in nonseptic group and septic neonates at the time
of diagnosis (Sepsis 1) and 4872 hours after initiation of treatment (Sepsis 2).
Novel Markers for Neonatal Sepsis 419In another study it was shown that within < 24 hours
after diagnosis serum levels of sTREM-1 were increased in
parallel with sepsis severity, being higher in severe sepsis
and septic shock.22 In a study conducted in mechanically
ventilated patients with pneumonia, Gibot et al21 found
higher levels of sTREM-1 in bronchoalveolar lavage fluid
samples taken from patients with a diagnosis of community-
acquired pneumonia and ventilator-associated pneumonia
than from those who did not have pneumonia. In anotherTable 3 Diagnostic accuracy of serum IL-6, sTREM-1, endocan,
Diagnostic
parameters
Cut-off
point
ROC AUC (95%-CI) p Sens
Biomarkers
IL-6 (ng/mL) 7 0.96 (0.9080.998) < 0.001 93.3
sTREM-1 (pg/mL) 450 0.97 (0.9310.998) < 0.001 93.3
Endocan (ng/mL) 22.5 0.80 (0.6740.923) < 0.001 76.7
I/T ratio 0.17 0.90 (0.8260.987) < 0.001 83.3
IL-6 Z interleukin-6; I/T ratio Z immature by total ratio; NLR Z
PLR Z positive likelihood ratio; PPV: positive predictive value; ROC
sTREM-1 Z soluble triggering receptor expressed on myeloid cells-1.study of the same group, they sequentially measured
plasma sTREM-1 concentrations in septic patients and found
that sTREM-1 concentrations remained stable or even
increased in nonsurvivors while they decreased in survivors.
For this reason, declining plasma sTREM-1 levels could
indicate a favorable clinical improvement during sepsis
follow-up. In our study, we found a significant decrease in
repeat sTREM-1 measurements (within 48e72 hours after
initiation of treatment) when compared with the initialand I/T ratio in septic neonates.
itivity (%) Specificity (%) PPV (%) NPV (%) PLR NLR
95 96.6 90.5 18.66 0.07
90 93.3 90 9.33 0.07
70 79.3 66.7 2.56 0.33
80 86.2 85.7 4.17 0.21
negative likelihood ratio; NPV Z negative predictive value;
AUC Z receiver-operating characteristic area under the curve;
Table 4 Univariate and multivariate logistic regression analysis of diagnostic markers as an indicator of sepsis.
Diagnostic markers p Unadjusted odds ratio* (95% CI) Adjusted odds ratioy (95% CI)
IL-6 (< 7 ng/mL) < 0.001 266.0 (22.503145.19) 157.4 (10.802293.54)
sTREM-1 (< 450 pg/mL) < 0.001 126.0 (16.26976.27)
Endocan (< 22.5 ng/mL) 0.002 7.7 (2.1427.49)
I/T ratio (< 0.17) < 0.001 20.0 (4.6685.85)
* Unadjusted odds ratio: The obtained value with univariate logistic regression analysis.
y Adjusted odds ratio: The obtained value with multivariate logistic regression analysis after the adjustment for other variables
(STREM-1, endocan, and I/T ratio).
420 M. Saldir et alvalues (at the 1st admission). We attributed this decline to
antibiotic response. Therefore, we also speculate that a
progressive decline in levels of sTREM-1 may indicate
favorable progress in neonates with LOS.
Endocan is a soluble dermatan sulfate proteoglycan that
is expressed and secreted by the vascular endothelium. It
has been studied as a novel endothelial cell dysfunction
marker in critically ill adults with sepsis, severe sepsis, and
septic shock.23 In a study conducted in ICU, Scherpereel
et al23 demonstrated that endocan blood level was related
to the severity of illness and outcome of the patients. In
another study, it was shown that an endocan fragment
(p14) increased in plasma with severe septic patients,
suggesting its likely contribution to the pathogenesis of
sepsis.24 In the present study, we found that endocan levels
significantly increased in septic neonates compared with
nonseptic neonates. Additionally, within 4872 hours after
treatment, the levels of endocan significantly decreased to
normal levels and the difference disappeared in comparison
with the nonseptic group.
Our data support the elevation of this molecule in septic
neonates. One important point is that the diagnostic value
of endocan cannot reach that of sTREM-1. This may be due
to the lack of septic shock and also endothelial dysfunction
in the study group. As a result, we suggest that sTREM-1 and
endocan may be used not only to predict sepsis, but also to
follow-up neonates with LOS. The AUC value of CRP was not
performed because it was taken into consideration the
differential diagnosis of sepsis. Although endocan and I/T
ratio were also statistically significant, they were not
considered clinically significant compared with IL-6 and
sTREM-1 as can be seen from the values of positive and
negative likelihood ratio (PLR and NLR; Table 3).
One limitation of this study was the low incidence of
culture-proven LOS. Neonates with probable sepsis were
assumed to be similar to those with culture-proven sepsis.
Furthermore, neonatal sepsis could not be ruled out solely
on the basis of a negative blood culture result.24 Exposure
of neonates to maternal antibiotic treatment during de-
livery increased the rate of false negative blood cultures. In
addition, the small blood volumes collected when obtaining
blood cultures (0.5e1.0 mL) and the high proportion of low
colony count bacteremia result in a diminished sensitivity
of blood cultures sepsis diagnosis.25
In conclusion, we report that serum sTREM-1 and endo-
can levels increase in septic neonates and that they both
decrease within 4872 hours of treatment. However,
diagnostic accuracy of circulating sTREM-1 seems to be
better than endocan but lower than IL-6. Soluble TREM-1and endocan represent promising novel biomarkers for
neonatal sepsis. Large multicentre trials are needed to
assess whether determining sTREM-1 and endocan in neo-
nates with LOS can improve the diagnosis and follow-up of
infection and reduce unnecessary antibiotic therapy.
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